Sandoz voluntarily recalls 24 lots of injectable methotrexate

10/27/2010 | Reuters

Novartis' Sandoz unit is recalling 24 lots of methotrexate, an injectable chemotherapy drug, after discovering glass particulates in the product. The recall affects vials of 50 milligrams per 2 milliliters and 250 milligrams per 10 milliliters. Sandoz has not received reports of adverse effects concerning the drug.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY